Prescriber Checklist/Acknowledgement Form for Prescribing Neotigason (acitretin) to Female Patients

The potential for pregnancy must be assessed for all female patients prescribed acitretin.

A woman has a potential for pregnancy if one of the following applies:

Is a sexually mature woman who:

1. Has not had a hysterectomy or bilateral oophorectomy

- 2. Is not in a natural post menopause for a minimum of 24 consecutive months
- (i.e. menstruated at a certain point in the last 24 consecutive months)

This checklist is to be completed by the Physician for all female patients prescribed acitretin and kept with patient notes to document compliance with the Acitretin Pregnancy Prevention Programme. After completion, a copy of this document should be given to the patient.

Acitretin belongs to the retinoid class of drugs that cause severe birth defects. Foetal exposure to acitretin, even for short periods, presents a high risk of congenital malformations. Acitretin is therefore strictly contraindicated in women of childbearing potential, unless all conditions in the Acitretin Pregnancy Prevention Programme are fulfilled.

As the prescribing doctor, you must make sure that the risk of serious harm from drug exposure during pregnancy is fully understood by all female patients before treating them with acitretin.

Before initiating acitretin therapy in a female patient, the following checklist must be completed and stored in the patient's notes. This checklist should also be used in all follow-up visits with women of childbearing potential.

Please use the patient reminder card to support your discussion with the patient.

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Please report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card scheme. You can report via:

• the Yellow Card website, <u>www.mhra.gov.uk/yellowcard</u>

- the free Yellow Card app available from the
 - → Apple App Store or Google Play Store
 - → some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) for healthcare professionals

Alternatively, you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours.

When reporting please provide as much information as possible. By reporting side effects, you can help provide more information on the safety of this medicine.

Adverse events may also be reported to Teva UK Limited via email to <u>medinfo@tevauk.com</u> or via phone on +44 (0) 207 540 7117.

Is the patient a woman of childbearing potential? Yes/No

If 'No' go to section 4.

Women of childbearing potential Review the below statements, explain them to the patient and record confirmation of this and acknowledgment from the patient in this form. If the answer to any of these questions is **NO**, acitretin must not be prescribed.

Is the patient suffering from a severe extensive refractory form of gsoriasis, palmoplantar pustular posinisis, severe competital ichtyposis and ichtyposiform dermatitis (ichen ruber planus of skin and mucous membranes, other severe and refractory forms of dermatitis characterised by dyskeratosis and/or hyperkeratosis.		Doctor confirm: I have explained this to my patient [YES/NO]	Patient confirm: I have understood this [YES/NO]
The patient understands that activetin belongs to a class of drugs (retinoids) known to cause severe birth defects and that they must not get pregnant whilst taking it. Activetin also increases the risk of miscarriage when taken during pregnancy. 2. Contraception The patient understands that she must consistently and correctly use at least 1 highly effective method of contraception (i.e. a user-independent form such as an intraurerine device or implant) or 2 complementary methods of birth control (i.e. userdependent forms such as oral contraceptive and barrier method) before and during treatment. The patient understands that the risk persists even after the medication is stopped and that she must not get pregnant within 3 years after stopping treatment. The patient has received advice on contraceptive failure. 3. Pregnancy Testing & Monthy Prescriptions The first prescription for active in an only be given after the patient has had one negative medically supervised pregnancy test. This is to make sure she is not already pregnant before starting treatment. Patient understands that in order to support regular follow up, including pregnancy testing and monitoring, ideally the prescription should be limited to 30 days. Patient understands that in order to support regular follow up, including pregnancy testing and monitoring, ideally the prescription of a airce starter stepping treatment. Patient understands the need for period of a years after stopping treatment. This is because the drug can stag in the body for 3 years after stopping treatment. This is because the drug can stag in the body for 3 years after stopping treatment. Patient understands that need for period of a years after stopping treatment. This is because the drug can stag in the body for 3 years after stopping treatment. This is because the drug can stag in the body for 3 years after stopping treatment. Patient understands the need for and agrees to pregnancy tests with 1-3 monthy intervals the advice treatment and also for a period of years after s	pustular psoriasis, severe congenital ichthyosis and ichthyosiform dermatitis, lichen ruber planus of skin and mucous membranes, other severe and refractory forms of dermatitis		
severe birth defects and that they must not get pregnant whilst taking it. Acitretin also increases the risk of miscarriage when taken during pregnancy. 2. Contraception The patient understands that she must consistently and correctly use at least 1 highly effective method of contraception (i.e. auser-independent form such as an intrauterine device or implant) or 2 complementary methods of birth control (i.e. userdependent forms such as an intrauterine device or implant) or 2 complementary methods of birth control (i.e. userdependent forms such as on intrauterine device or implant) or 2 complementary methods of birth control (i.e. userdependent forms such as one incuraceptive and barrier method) before and during treatment. The patient nuderstands that the risk persists even after the medication is stopped and that she must not get pregnant within 3 years after stopping treatment. The patient is more received advice on contraception, which is appropriate for her and has committed to using it throughout the risk period. 3. Cregnacy Testing & Monthly Prescriptions The first prescription for a citretin can only be given after the patient has had one negative medically supervised pregnancy test. This is to make sure she is not already pregnant before starling treatment. Patient understands that in order to support regular follow up, including pregnancy testing and monitoring, ideally the prescription on ould be limited to 30 days. Patient understands the need for and agrees to pregnancy testing before, during and after treatment. Patient understands the need for a periodi of a years after stopping treatment. This is because the drug can staj in the body for 3 years after the should be limited to 30 days. The patient has received a day of years after the should be refereed to an unborn baby if pregnancy occurs. The contraceptive methods and pregnancy test results should be refereed to an unborn baby if pregnancy occurs. The patient has received a copy of the educational package. The patient has received a copy of	1. Teratogenicity		
The patient understands that she must consistently and correctly use at least 1 highly effective method of contraception (i.e. a user-independent form such as an intrauterine device or implant) or 2 complementary methods of birth control (i.e. userdependent forms such as oral contraceptive and barrier method) before and during treatment. The patient understands that the risk period. The first prescription for activetion on the patient has had one negative medically supervised pregnancy test. This is to make sure she is not already pregnant before starting treatment. Patient understands that in order to support regular follow up, including pregnancy testing and monitoring, ideally the prescription should be limited to 30 days. Patient understands that end for and agrees to pregnancy test with 1-3 monthly intervals throughout the risk of 0 for 3 years after stopping treatment. This is because the drug can stay in the body for 3 years after stopping treatment. Patient understands the need for periodic pregnancy test with 1-3 monthly intervals throughout the risk of 0 for 3 years after stopping treatment. The contraceptive methods and pregnancy test should be recorded in the patient's medical records. The patient understands that excerve da copy of the educational package. The contraceptive methods and pregnancy test subped and the patient's medical records. The patient knows to contact their doctor if the	severe birth defects and that they must not get pregnant whilst taking it. Acitretin also		
effective method of contraception (i.e. a user-independent form such as an intrauterine device or implementary methods of birth control (i.e. userdependent forms such as oral contraceptive and barrier methods) before and during treatment. The patient understands that the risk persists even after the medication is stopped and that she must not get pregnant within 3 years after stopping treatment. The patient has received advice on contraceptive, millor appropriate for her and has committed to using it throughout the risk period. The patient is aware of the risk of contraceptive failure. 3. Pregnancy Testing & Monthly Prescription 5 The first prescription for actiretin can only be given after the patient has had one negative medically supervised pregnancy test. This is to make sure she is not already pregnant before starting treatment. Patient understands that in order to support regular follow up, including pregnancy testing and monitoring, ideally the prescription should be limited to 30 days. Patient understands the need for periodic pregnancy tests with 1-3 monthly intervals throughout treatment and also for a period of 3 years after stopping treatment. This is because the drug can stay in the body for 3 years after the last dose and can damage an unborn baby if pregnancy occurs. The patient has received a copy of the educational package. The patient has received a copy of the educational package. The patient has received a copy of the educational package. The patient specialised or experienced in teratology for advice. 4. Other Precautions Patient understands that actiretin has been prescribed to her only and must not be shared with others. Patient understands that actiretin has been prescribed to her only and must not be shared with others. Patient understands that here to do of it the patient should be referred to an expert physician specialised or experienced in the robus period. For patient is precised a copy of the educational package. Patient understands that actiretin has been prescribed to her only a	2. Contraception		
she must not get pregnant within 3 years after stopping treatment. The patient has received advice on contraception, which is appropriate for her and has committed to using it throughout the risk period. The patient is aware of the risk of contraceptive failure. 3. Pregnancy Testing & Monthly Prescriptions The first prescription for actiretin can only be given after the patient has had one negative medically supervised pregnancy test. This is to make sure she is not already pregnant before starting treatment. Patient understands that in order to support regular follow up, including pregnancy testing and monitoring, ideally the prescription should be limited to 30 days. Patient understands the need for and agrees to pregnancy testing before, during and after treatment. Patient understands the need for apriod of 3 years after stopping treatment. This is because the drug can staj in the body for 3 years after the last dose and can damage an unborn baby if pregnancy occurs. The patient has received a copy of the educational package. The patient knows to contact their doctor if they have unprotected sex, miss their period, become pregnant, or suppert that year prescribed to ther only and must not be shared with others. Patient understands that she must not donate blood during treatment with acitretin and for a expert physician specialized or experienced to the rootly and must not be shared with others. Patient understands that she must not donate blood during treatment with acitretin and for 3 years after discontinuation due to the potential risk to the foetus of a pregnant transfusion recipient. Patient understands that she must hot donate blood during treatment transfusion recipient. Patient understands that she must hot donate blood during treatment for 3 years after discontinuation due to the potential risk to the foetus of a pregnant transfusion recipient. Patient understands that she must hot donate blood during treatment with acitretin and for 3 years after discontinuation due to the potential risk to the foe	effective method of contraception (i.e. a user-independent form such as an intrauterine device or implant) or 2 complementary methods of birth control (i.e. userdependent forms		
committed to using it throughout the risk period. Image: Committed to using it throughout the risk period. The patient is aware of the risk of contraceptive failure. Image: Committed to using it throughout the risk period. 3. Pregnancy Testing & Monthly Prescriptions Image: Committed to using it throughout the risk period. The first prescription for a curretin can only be given after the patient has had one negative medically supervised pregnancy test. This is to make sure she is not already pregnant before starting treatment. Patient understands that in order to support regular follow up, including pregnancy testing and monitoring, ideally the prescription should be limited to 30 days. Patient understands the need for and agrees to pregnancy testing before, during and after treatment. Patient understands the need for periodic pregnancy tests with 1-3 monthly intervals throughout treatment and also for a period of 3 years after the last dose and can damage an unborn baby if pregnancy occurs. The patient has received a copy of the educational package. The patient knows to contact their doctor if they have unprotected sex, miss their period, become pregnant, or suspect that they have become pregnant during the risk period. If pregnancy occurs, treatment must be stopped and the patient should be referred to an expert physician specialised or experienced in teratology for advice. 4. Other Precautions Patient understands that a citretin has been prescribed to her only and must not be shared with others. Patient understands that se must not d			
3. Pregnancy Testing & Monthly Prescriptions The first prescription for acitretin can only be given after the patient has had one negative medically supervised pregnancy test. This is to make sure she is not already pregnant before starting treatment. Patient understands that in order to support regular follow up, including pregnancy testing and monitoring, ideally the prescription should be limited to 30 days. Patient understands the need for and agrees to pregnancy tests with 1-3 monthly intervals throughout treatment and also for a period of 3 years after stopping treatment. This is because the drug can stay in the body for 3 years after stopping treatment. This is because the drug can stay in the body for 3 years after the last dose and can damage an unborn baby if pregnancy occurs. The patient has received a copy of the educational package. The patient knows to contact their doctor if they have unprotected sex, miss their period. If pregnancy occurs, treatment must be stopped and the patient should be referred to an expert physician specialised or experienced in teratology for advice. 4. Other Precautions Patient understands that semust not donate blood during treatment with acitretin and for 3 years after the last dose and pregnancy occurs. The patient has received a copy of the educational package. The patient shows to contact their doctor if they have unprotected sex, miss their period. If pregnancy occurs, treatment must be stopped and the patient should be referred to an expert physician specialised or experienced in teratology for advice. 4. Other Precautions Patient understands that she must not donate			
The first prescription for acitretin can only be given after the patient has had one negative medically supervised pregnancy test. This is to make sure she is not already pregnant before starting treatment. Patient understands that in order to support regular follow up, including pregnancy testing and monitoring, ideally the prescription should be limited to 30 days. Patient understands the need for and agrees to pregnancy testing before, during and after treatment. Patient understands the need for periodic pregnancy tests with 1-3 monthly intervals throughout treatment and also for a period of 3 years after stopping treatment. This is because the drug can stay in the body for 3 years after the last dose and can damage an unborn baby if pregnancy occurs. The contraceptive methods and pregnancy test results should be recorded in the patient's medical records. The patient knows to contact their doctor if they have unprotected sex, miss their period, become pregnant, or suspect that they have become pregnant during the risk period. If pregnancy occurs, treatment must be stopped and the patient should be referred to an expert physician specialised or experienced in teratology for advice. 4. Other Precautions Patient understands that she must not donate blood during treatment with acitretin and for 3 years after to be fore so a pregnant transfusion recipient. Doctor Signature*	The patient is aware of the risk of contraceptive failure.		
medically supervised pregnancy test. This is to make sure she is not already pregnant before starting treatment. Patient understands that in order to support regular follow up, including pregnancy testing and monitoring, ideally the prescription should be limited to 30 days. Patient understands the need for and agrees to pregnancy testing before, during and after treatment. Patient understands the need for periodic pregnancy tests with 1-3 monthly intervals throughout treatment and also for a period of 3 years after stopping treatment. This is because the drug can stay in the body for 3 years after the last dose and can damage an unborn baby if pregnancy occurs. The contraceptive methods and pregnancy test results should be recorded in the patient's medical records. The patient has received a copy of the educational package. The patient knows to contact their doctor if they have unprotected sex, miss their period, become pregnant, or suspect that they have become pregnant during the risk period. If pregnancy occurs, treatment must be stopped and the patient should be referred to an expert physician specialised or experienced in teratology for advice. 4. Other Precautions Patient understands that acitretin has been prescribed to her only and must not be shared with others. Patient understands that be used to be potential risk to the foetus of a pregnant transfusion recipient. Doctor Signature Patient Signature*	3. Pregnancy Testing & Monthly Prescriptions	1	
and monitoring, ideally the prescription should be limited to 30 days. The second seco	medically supervised pregnancy test. This is to make sure she is not already pregnant before		
treatment. Image: Construction of the second of the se			
throughout treatment and also for a period of 3 years after stopping treatment. This is because the drug can stay in the body for 3 years after the last dose and can damage an unborn baby if pregnancy occurs. The contraceptive methods and pregnancy test results should be recorded in the patient's medical records. The patient has received a copy of the educational package. The patient knows to contact their doctor if they have unprotected sex, miss their period, become pregnant, or suspect that they have become pregnant during the risk period. If pregnancy occurs, treatment must be stopped and the patient should be referred to an expert physician specialised or experienced in teratology for advice. 4. Other Precautions Patient understands that acitretin has been prescribed to her only and must not be shared with others. Patient discontinuation due to the potential risk to the foetus of a pregnant transfusion recipient. Doctor Signature*			
medical records. Image: Control of the educational package. The patient has received a copy of the educational package. Image: Control of the educational package. The patient knows to contact their doctor if they have unprotected sex, miss their period, become pregnant, or suspect that they have become pregnant during the risk period. Image: Control of the education of	throughout treatment and also for a period of 3 years after stopping treatment. This is because the drug can stay in the body for 3 years after the last dose and can damage an		
The patient knows to contact their doctor if they have unprotected sex, miss their period, become pregnant, or suspect that they have become pregnant during the risk period. If pregnancy occurs, treatment must be stopped and the patient should be referred to an expert physician specialised or experienced in teratology for advice. If pregnancy occurs, treatment must be stopped and the patient should be referred to an expert physician specialised or experienced in teratology for advice. 4. Other Precautions Patient understands that acitretin has been prescribed to her only and must not be shared with others. Patient understands that she must not donate blood during treatment with acitretin and for 3 years after discontinuation due to the potential risk to the foetus of a pregnant transfusion recipient. Doctor Signature Patient Signature*			
become pregnant, or suspect that they have become pregnant during the risk period. If pregnancy occurs, treatment must be stopped and the patient should be referred to an expert physician specialised or experienced in teratology for advice. 4. Other Precautions Patient understands that acitretin has been prescribed to her only and must not be shared with others. Patient understands that acitretin has been prescribed to her only and must not be shared with others. Patient understands that she must not donate blood during treatment with acitretin and for 3 years after discontinuation due to the potential risk to the foetus of a pregnant transfusion recipient. Doctor Signature	The patient has received a copy of the educational package.		
an expert physician specialised or experienced in teratology for advice. 4. Other Precautions Patient understands that acitretin has been prescribed to her only and must not be shared with others. 9 Patient understands that she must not donate blood during treatment with acitretin and for 3 years after discontinuation due to the potential risk to the foetus of a pregnant transfusion recipient. 9 Doctor Signature Patient Signature*			
Patient understands that acitretin has been prescribed to her only and must not be shared with others. Patient understands that she must not donate blood during treatment with acitretin and for 3 years after discontinuation due to the potential risk to the foetus of a pregnant transfusion recipient. Doctor Signature Patient Signature*			
with others. Patient understands that she must not donate blood during treatment with acitretin and for 3 years after discontinuation due to the potential risk to the foetus of a pregnant transfusion recipient. Doctor Signature Patient Signature*	4. Other Precautions		
3 years after discontinuation due to the potential risk to the foetus of a pregnant transfusion recipient. Doctor Signature Patient Signature*			
Patient Signature*	3 years after discontinuation due to the potential risk to the foetus of a pregnant transfusion		
	Doctor Signature		
Date	Patient Signature*		
	Date		

*Signature of parent or legal guardian is necessary if the patient is under the age of 18

GEN-GB-NP-00334 Version 2 Date of Preparation: September 2024 MHRA Approval Date: October 2024

Provided by Teva UK Limited, Ridings Point, Whistler Drive, Castleford, WF10 5HX. United Kingdom